KBC Group
RVMD icon

KBC Group’s Revolution Medicines RVMD Stock Holding History

KBC Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.27M Buy
28,136
+12,741
+83% +$1.86M 0.01% 494
2026
Q1 		$1.5M Buy
15,395
+11,196
+267% +$1.13M ﹤0.01% 696
2025
Q4 		$334K Hold
4,199
– – ﹤0.01% 774
2025
Q3 		$196K Hold
4,199
– – ﹤0.01% 913
2025
Q2 		$154K Sell
4,199
-1,932
-32% -$74.2K ﹤0.01% 975
2025
Q1 		$217K Buy
6,131
+1,152
+23% +$46.8K ﹤0.01% 1025
2024
Q4 		$218K Buy
4,979
+1,758
+55% +$88.7K ﹤0.01% 1081
2024
Q3 		$146K Buy
3,221
+368
+13% +$16K ﹤0.01% 1067
2024
Q2 		$111K Buy
2,853
+592
+26% +$22.1K ﹤0.01% 1110
2024
Q1 		$73K Hold
2,261
– – ﹤0.01% 1308
2023
Q4 		$65K Buy
2,261
+1,034
+84% +$24.8K ﹤0.01% 1346
2023
Q3 		$34K Buy
+1,227
New +$36.4K ﹤0.01% 1731

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KBC Group's RVMD Position: Q2 2026 in Review

KBC Group increased its Revolution Medicines (RVMD) stake by 83% in Q2 2026, buying an estimated $1.86M and bringing the position to 28,136 shares worth $5.27M. The position accounts for 0.01% of the portfolio, ranked #494.

KBC Group first reported a position in RVMD in Q3 2023 and has held it in 12 quarters since. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • KBC Group held 28,136 shares of Revolution Medicines worth $5.27M as of Q2 2026.
  • KBC Group bought 12,741 Revolution Medicines shares in Q2 2026, an estimated $1.86M.
  • Revolution Medicines made up 0.01% of KBC Group's portfolio in Q2 2026, its #494 holding.
  • KBC Group first reported a position in Revolution Medicines in Q3 2023 and has held it in 12 quarters since.
  • 693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.